tiprankstipranks
Advertisement
Advertisement
AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy
PremiumCompany AnnouncementsAstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy
2d ago
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Guggenheim
Premium
The Fly
AstraZeneca price target raised to 16,500 GBp from 16,000 GBp at Guggenheim
2d ago
Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories
Premium
Market News
Morning News Wrap-Up: 3/27/26: Today’s Biggest Stock Market Stories
4d ago
De‑Risking a Multibillion-Dollar COPD Opportunity: Buy Rating on AstraZeneca Following Strong Tozorakimab Phase III Data
PremiumRatingsDe‑Risking a Multibillion-Dollar COPD Opportunity: Buy Rating on AstraZeneca Following Strong Tozorakimab Phase III Data
5d ago
AstraZeneca Stock (AZN) Soars after Successful $5B Lung Disease Treatment Trial
Premium
Market News
AstraZeneca Stock (AZN) Soars after Successful $5B Lung Disease Treatment Trial
5d ago
AstraZeneca announces tozorakimab met primary endpoint in Phase III trials
Premium
The Fly
AstraZeneca announces tozorakimab met primary endpoint in Phase III trials
5d ago
Better Vanguard ETF? Vanguard Pacific (VPL) or Vanguard Europe (VGK)
PremiumMarket NewsBetter Vanguard ETF? Vanguard Pacific (VPL) or Vanguard Europe (VGK)
12d ago
AstraZeneca Adds Employee Scheme Shares to LSE Listing
Premium
Company Announcements
AstraZeneca Adds Employee Scheme Shares to LSE Listing
12d ago
AstraZeneca Halts Egyptian COPD Burden Study, Trimming Near-Term Data Upside
Premium
Company Announcements
AstraZeneca Halts Egyptian COPD Burden Study, Trimming Near-Term Data Upside
14d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100